Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
SK bioscience, a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in South Korea (KR). Founded in 2017, the company has rapidly established itself as a leader in vaccine development and biopharmaceuticals, focusing on innovative solutions to address global health challenges.
With a strong emphasis on research and development, SK bioscience offers a range of core products, including vaccines for infectious diseases, which are distinguished by their advanced technology and commitment to safety. The company has achieved significant milestones, including partnerships with global health organisations, enhancing its market position and reputation for excellence.
As a key contributor to the biopharmaceutical landscape, SK bioscience continues to drive advancements in healthcare, making a meaningful impact on public health both locally and internationally.
+35 vs industry average
SK bioscience’s score of 77 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
SK bioscience Climate Performance & Commitments
SK bioscience, a pharmaceutical preparation manufacturer headquartered in KR, reported approximately 58.3 million kg CO2e in total carbon emissions for 2024. This figure includes Scope 1 emissions of around 10.4 million kg CO2e, Scope 2 emissions of approximately 15.0 million kg CO2e, and Scope 3 emissions totalling about 32.9 million kg CO2e. Key contributors to Scope 3 emissions in 2024 included purchased goods and services (approximately 19.5 million kg CO2e) and end-of-life treatment of sold products (about 7.8 million kg CO2e).
In 2023, SK bioscience's total carbon emissions were approximately 41.4 million kg CO2e, comprising around 5.9 million kg CO2e from Scope 1, 13.8 million kg CO2e from Scope 2, and 21.8 million kg CO2e from Scope 3.
For 2022, the company's reported Scope 1 emissions were approximately 5.2 million kg CO2e, and Scope 2 emissions were about 13.3 million kg CO2e. No Scope 3 emissions data was disclosed for 2022.
In 2021, SK bioscience reported Scope 3 emissions of approximately 153.4 million kg CO2e, and combined Scope 1 and 2 emissions of about 16.9 million kg CO2e.
While SK bioscience directly reports its climate performance data, its Science Based Targets initiative (SBTi) commitments are cascaded from its parent company, SK Chemicals Co.,Ltd. The company has not publicly disclosed specific carbon reduction targets or participation in initiatives like RE100 or Climate Pledge.
No climate goals have been disclosed for SK bioscience yet.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more